South & Central America Therapeutic Vaccines Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The South & Central America therapeutic vaccines market size is expected to reach US$ 6,998.78 thousand by 2031 from US$ 3,370.35 thousand in 2024. The market is estimated to record a CAGR of 11.0% from 2024–2031. 

Executive Summary and South & Central America Therapeutic Vaccines Market Analysis:

The therapeutic vaccines market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The market growth in this region is attributed to large population, expanding healthcare infrastructure, and growing government focus on healthcare innovation. Additionally, rising healthcare expenditure in the region, and increased demand for treatments due to rising chronic disease further propels the growth of the market.

South & Central America Therapeutic Vaccines Market Strategic Insights

Get more information on this report Request Free Sample PDF

South & Central America Therapeutic Vaccines Market Segmentation Analysis

Key segments that contributed to the derivation of the therapeutic vaccines market analysis are product, technology, and end user.

• By product, the therapeutic vaccines market is segmented into cancer vaccines, infectious disease vaccines, and others. The cancer vaccines held the largest share of the market in 2024.
• By technology, the therapeutic vaccines market is bifurcated into allogenic vaccine and autologous. The allogenic held the largest share of the market in 2024.
• By end user, the therapeutic vaccines market is segmented into hospital, clinics, and others. The hospital held the largest share of the market in 2024.

South & Central America Therapeutic Vaccines Market Outlook

As the global demand for innovative treatment options rises, the therapeutic vaccines sector has witnessed robust investments and advancements in vaccine development, driven largely by the rising number of clinical candidates progressing through various stages of development. Innovative R&D efforts in biotechnology are yielding cutting-edge therapeutic vaccines that target various diseases, particularly newer infections and chronic ones such as cancer. Moderna's mRNA-4157 is currently in phase 2 trials, with early-stage results showing promising potential in combination with checkpoint inhibitors for melanoma treatment. In addition to oncology, the therapeutic vaccine pipeline is also growing in areas such as autoimmune diseases and infectious diseases (HIV, HPV, and HBV infections).

Several companies are investing in scientific and technical excellence to develop and introduce new therapeutic vaccines. With the expanding pipeline of vaccine candidates targeting diverse diseases, therapeutic vaccines hold immense potential to address unmet medical needs. Below is the product pipeline for therapeutic vaccines targeting various conditions:

With strong ongoing clinical trials, the market's prospects are expected to expand, offering new treatment options for patients worldwide and addressing unmet medical needs in areas where current treatments are ineffective. Thus, a strong pipeline of candidates for therapeutic vaccines signifies lucrative growth opportunities for the therapeutic vaccines market.

South & Central America Therapeutic Vaccines Market Country Insights

Based on country, the South & Central America therapeutic vaccines market comprises the Argentina, Brazil, and the Rest of South & Central America. Brazil held the largest share in 2024.

In Brazil, the therapeutic vaccine market holds considerable potential owing to its large population, expanding healthcare infrastructure, and growing government focus on healthcare innovation. According to the Pan American Health Organization, Brazil had more than 30 million older adults aged 60 and above as of 2022, indicative of 13% of the country's population. By 2030, the number of people from this age group will reach nearly 50 million, which will be 24% of its total population. The World Health Organization (WHO) and the Brazilian Institute of Geography and Statistics reported that the geriatric population in Brazil (agedandthinsp;60 and older) is expected to reach ~55 million by 2040. Brazil witnessed a high incidence of chronic diseases and cancers, which resulted in significant health burdens. According to GLOBOCAN 2020, there were 592,212 cancer cases across the country, comprising 300,144 males and 292,098 women. Brazil has a high incidence of cancer, and therapeutic vaccines could significantly reduce the disease's burden, benefiting from both global innovations and Brazil's unique epidemiological landscape. This creates a large potential market for vaccines that can manage or treat these conditions. Additionally, as the country's healthcare professionals become more familiar with the concept of personalized medicine and targeted therapies, the demand for therapeutic vaccines is expected to increase in the coming years. This growing knowledge base, coupled with rising public interest in novel medical treatments, opens up new opportunities for vaccine development and commercialization.

South & Central America Therapeutic Vaccines Market Report Highlights

South & Central America Therapeutic Vaccines Market Company Profiles

Some of the key players operating in the market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South & Central America Therapeutic Vaccines Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis, and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

South & Central America Therapeutic Vaccines Market Country and Regional Insights